Gliflozins, a new hope for heart failure? systematic review
DOI:
https://doi.org/10.56294/piii2023166Keywords:
Heart Failure, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure/Mortality, Systematic Review, Diabetes Mellitus, Type 2/drug therapyAbstract
Background: Heart Failure (HF) is a public health problem with high morbidity and mortality rates, as well as resource consumption. Sodium-glucose cotransporter type 2 inhibitors (SGLT-2 inhibitors), originally developed for type 2 diabetes, have become an attractive therapeutic option for HF. Recent studies have shown that gliflozins, a type of SGLT-2 inhibitor, reduce the risk of cardiovascular death and hospitalization for HF compared to placebo. Further studies are needed to confirm these findings and establish their place in the current therapy for HF. Material and methods: A systematic review of studies published in PUBMED evaluating the use of gliflozins, a subtype of InSGLT-2, in patients with heart failure was performed. Results: Based on the articles analyzed, a total of 25,960 patients with heart failure were included, who were studied in 4 different studies. Conclusion: The use of gliflozins in patients with heart failure was found to be associated with a significant reduction in the risk of cardiovascular death, hospitalization for heart failure, and adverse cardiovascular events compared with placebo
References
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner MH, et al. 2013 ACC F/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128: e24 0-e327.
Bozkurt B, Coats AJ S, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021; 27:3 8-413.
O’Connor CM, Hasselblad V, Mehta RH, Tasissa G, Califf RM, Fiuzat M, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol 2010 ;55 :872 -878.
Jessup M, Brozena S. Heart Failure. N Engl J Med 2003; 348:2007–18.
Filippatos G, Khan SS, Ambrosy AP, Cleland JGF, Collins SP, Lam CSP, et al. International Registry to assess medical Practice with Longitudinal observation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail 2015; 17:527-533.
McMurray JJJ V. Improving outcomes in heart failure: a personal perspective. Eur Heart J 2015; 36:3467-
Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-16.
Fairman E, Thierer J, Rodríguez L, Blanco P, Ghetta J, Fernández S y col. Registro Nacional de Internación por Insuficiencia Cardíaca 2007. Rev Argent Cardiol 2009; 77:33-9.
Thierer J, Iglesias D, Ferrante D, Marino J, Diez M, Rolong B y col. Registro Nacional de Internación por Insuficiencia Cardíaca. Factores responsables, evolución hospitalaria y predictores de mortalidad. Rev Argent Cardiol 2002; 70:261-73.
Nohria A, Tsang S, Fang J, Lewis E, Jarcho J, Mudge G, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol ; 41:1797-804.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667
Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al. Body mass index and prognosis in patients with chronic heart failure: insigh ts from the Candesartan in Heart failure: assessment of reduction of mortality and morbidity (CHARM) program. Circulation 2007;116 :627 – 636.
CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac insufficiency bisoprolol Study II (CIBIS-II). Circulation 1994; 90: 1765-1773.
Pitt B, Zannad F, Remme WJ, Cody R, castaigne A, Pérez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
Pitt B, Gheorghiade M, Zannad F, Anderson JL, Van Veldhuisen DJ, Parkhomenko A, et al...Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction Eur J Heart Fail 2006; 8:295-301.
CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999,353: 9-13.
Ogunyankin KO, Singh BN. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. Am J Cardiol 1999, 4; 76-82.
Bohn M; Borre JS; Komajda M; López Sendon J; et at (2013 ) Heart et at baseline influences the efect of ivabradina on cardiovascular outcomes in chronic Heart failure: análisis from the SHIFT Study. Clin Res Cardiol 2013; 102: 11- 22.
Cavallari I, Maddalon Ei, Nusca A, Tuccinardi D, Buzzetti, R Pozzilli P, et al. SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. Am J Cardiovasc Drugs 2022; 22:3,263-270.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S,et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med2015; 373:2117–2128.
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. PMID: 32865377.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. PMID: 31535829.
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Sabatine, M. S., & DECLARE–TIMI 58 Investigators (2021). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, 398(10295), 129–139. https://doi.org/10.1016/S0140-6736(21)00731-X
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
Bhatt AS, Cooper LB, Ambrosy AP, et al. Interaction of Body Mass Index on the Effects of Sodium-Glucose Cotransporter 2 Inhibition With Empagliflozin in Heart Failure: An Analysis From the EMPEROR-Reduced Trial. J Am Heart Assoc. 2022;11(2):e022140. doi:10.1161/JAHA.121.022140
Januzzi JL Jr, Butler J, Jarolim P, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Heart Failure and Reduced Ejection Fraction: Insights From the CANDLE Trial. Circulation. 2021;143(10):987-989. doi:10.1161/CIRCULATIONAHA.120.050865
Muscoli S, Barillà F, Tajmir R, Meloni M, Della Morte D, Bellia A, Di Daniele N, Lauro D, Andreadi A. The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics. 2022 Aug 18;14(8):1730. doi: 10.3390/pharmaceutics14081730. PMID: 36015359; PMCID: PMC9416279.
Tanaka A, Node K. Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment. Diabetol Int. 2020 Jun 11;11(3):252-260. doi: 10.1007/s13340-020-00445-7. PMID: 32802706; PMCID: PMC7387386.
Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-2117. doi:10.1007/s00125-018-4683-6
Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020 Dec;7(6):3298-3309. doi: 10.1002/ehf2.13169. Erratum in: ESC Heart Fail. 2021 Jun;8(3):2362. PMID: 33586910; PMCID: PMC7755023.
Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596. PMID: 30295797; PMCID: PMC6302261.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ana Beatriz Golin Brustolin, Rafael Porcile (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
